About: http://data.cimple.eu/news-article/3a013e5ccfeaa7e99db2a4ce2670fb97327971d985cfaf06c1c45f20     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • US health experts said Tuesday they are halting clinical trials of convalescent blood plasma in patients with mild to moderate Covid symptoms after preliminary results showed no benefit from the treatment. The trial that began in August involved just over 500 people who went to emergency rooms but did not need to be hospitalized. The people chosen for the study also had risk factors such as obesity, high blood pressure, diabetes or heart trouble. Some of them received the treatment -- blood plasma from people who had Covid and overcame it -- and others got a placebo. Doctors looked at how many needed additional care or outright hospitalization, or who died, in the 15 days after undergoing the treatment. An independent group of experts determined that while the convalescent plasma intervention caused no harm, it was unlikely to benefit patients, the National Institutes of Health said. Convalescent plasma is the liquid part of blood from a Covid patient that recovered. It contains anti-bodies produced by the body after being infected. In late October a study carried out in India and published in the medical journal BMJ said the treatment offered limited effectiveness. It did not reduce mortality or keep people with moderate Covid symptoms from developing a serious case. More than 100,000 people have received the treatment in the US since the start of the pandemic and many more elsewhere in the world, the NIH said. In late August, at the persistent request of then president Donald Trump, the US Food and Drug Administration granted emergency authorization for transfusions of blood plasma from recovered Covid patients to people who were hospitalized with the disease. The then head of the FDA, Stephen Hahn, acknowledged an error at a press conference with Trump, saying he had cited figures that overestimated the benefits of the treatment. The FDA recently restricted its emergency authorization to use of plasma only with a high concentration of antibodies and for patients hospitalized with early stages of Covid or with a limited ability to produce antibodies. la/iba/dw/bgs
schema:headline
  • US halts trials of plasma transfusions for Covid patients
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software